Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension
- PMID: 10937568
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension
Abstract
Purpose: To compare the around-the-clock intraocular pressure (IOP) reduction induced by timolol 0.5%, latanoprost 0.005%, and dorzolamide in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Methods: In this crossover trial, 20 patients with POAG (n = 10) or OHT (n = 10) were treated with timolol, latanoprost, and dorzolamide for 1 month. The treatment sequence was randomized. All patients underwent measurements for four 24-hour tonometric curves: at baseline and after each 1-month period of treatment. The patients were admitted to the hospital, and IOP was measured by two well-trained evaluators masked to treatment assignment. Measurements were taken at 3, 6, and 9 AM and noon and at 3, 6, and 9 PM and midnight by handheld electronic tonometer (TonoPen XL; Bio-Rad, Glendale, CA) with the patient supine and sitting, and a Goldmann applanation tonometer (Haag-Streit, Bern, Switzerland) with the patient sitting at the slit lamp. Systemic blood pressure was recorded at the same times. The between-group differences were tested for significance by means of parametric analysis of variance. The circadian IOP curve of a small group of untreated healthy young subjects was also recorded using the same procedures. To compare the circadian IOP rhythms in the POAG-OHT and control groups, the acrophases for each subject were calculated.
Results: When Goldmann sitting values were considered, all the drugs significantly reduced IOP in comparison with baseline at all times, except for timolol at 3 AM. Latanoprost was more effective in lowering IOP than timolol at 3, 6, and 9 AM (P = 0.03), noon (P = 0.01), 9 PM, and midnight (P = 0.05) and was more effective than dorzolamide at 9 AM, noon (P = 0.03), and 3 and 6 PM (P = 0.04). Timolol was more effective than dorzolamide at 3 PM (P = 0.05), whereas dorzolamide performed better than timolol at midnight and 3 AM (P = 0.05). An ancillary finding of this study was that in the group of healthy subjects, the pattern of IOP curve was different that in patients with eye disease.
Conclusions: Latanoprost seemed to lead to a fairly uniform circadian reduction in IOP, whereas timolol seemed to be less effective during the nighttime hours. Dorzolamide was less effective than latanoprost but led to a significant reduction in nocturnal IOP. The reason for the difference in the pattern of the IOP curve of healthy subjects is currently unknown and deserves further investigation.
Similar articles
-
Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2917-23. doi: 10.1167/iovs.05-1253. Invest Ophthalmol Vis Sci. 2006. PMID: 16799034 Clinical Trial.
-
Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.Ophthalmic Res. 2007;39(1):24-31. doi: 10.1159/000097903. Epub 2006 Dec 11. Ophthalmic Res. 2007. PMID: 17164574 Clinical Trial.
-
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.Ophthalmology. 2006 Feb;113(2):239-46. doi: 10.1016/j.ophtha.2005.10.045. Ophthalmology. 2006. PMID: 16458092 Clinical Trial.
-
The effect of latanoprost on circadian intraocular pressure.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S90-6. doi: 10.1016/s0039-6257(02)00296-5. Surv Ophthalmol. 2002. PMID: 12204704 Review.
-
Latanoprost versus combined timolol and dorzolamide.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S148-54. doi: 10.1016/s0039-6257(02)00290-4. Surv Ophthalmol. 2002. PMID: 12204712 Review.
Cited by
-
Overnight Safety Evaluation of a Multi-Pressure Dial in Eyes with Glaucoma: Prospective, Open-Label, Randomized Study.Clin Ophthalmol. 2020 Sep 21;14:2739-2746. doi: 10.2147/OPTH.S256891. eCollection 2020. Clin Ophthalmol. 2020. PMID: 33061256 Free PMC article.
-
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1065-71. doi: 10.1007/s00417-011-1650-8. Epub 2011 Apr 16. Graefes Arch Clin Exp Ophthalmol. 2011. PMID: 21499770 Clinical Trial.
-
Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.Jpn J Ophthalmol. 2021 Sep;65(5):598-607. doi: 10.1007/s10384-021-00856-2. Epub 2021 Jul 19. Jpn J Ophthalmol. 2021. PMID: 34279749 Clinical Trial.
-
Prostanoid receptor agonists for glaucoma treatment.Jpn J Ophthalmol. 2021 Sep;65(5):581-590. doi: 10.1007/s10384-021-00844-6. Epub 2021 Jul 6. Jpn J Ophthalmol. 2021. PMID: 34228229 Review.
-
Glaucoma management: relative value and place in therapy of available drug treatments.Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286. Ther Adv Chronic Dis. 2014. PMID: 24381726 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical